The ministry of chemicals and fertilizers announced successful completion of thirty-two projects under the Production Linked Incentive (PLI) scheme, which is focused on boosting domestic production of essential key starting materials (KSMs), drug intermediates, and active pharmaceutical ingredients (APIs).
The projects, with a combined annual capacity of 56,679 metric tons, are expected to significantly strengthen India’s pharmaceutical supply chain and reduce reliance on imports. The PLI scheme, with a financial allocation of ₹6,940 crore, is designed to enhance the local production of bulk drugs and improve supply chain resilience.
Since its inception, the scheme has attracted considerable interest, with 249 applications submitted and 48 projects approved. Among these, 13 projects are being developed by ten micro, small, and medium enterprises (MSMEs). The completion of the 32 projects represents a major milestone, while the remaining 16 projects are still in progress.
The government is actively supporting the regulatory approval process, including environmental clearances and drug manufacturing licenses, with state governments playing a crucial role in expediting these approvals to ensure timely project completion.
As reported by devdiscourse.com, the scheme has already surpassed its initial investment target of ₹3,938 crore, with current investments reaching ₹4,024 crore, indicating strong industry confidence in India’s pharmaceutical sector.
